CTSH — Cognizant Technology Solutions Corporation

Cognizant Technology Solutions (CTSH) Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 Revenue: $5.3 billion, up 3.8% year-over-year in constant currency, all organic.
• Full-Year Revenue: $21.1 billion, representing a 6.4% increase in constant currency.
• Adjusted Operating Margin: 16% in Q4, up 30 basis points year-over-year; full-year adjusted operating margin at 15.8%, up 50 basis points.
• Adjusted Diluted EPS: $1.35 for Q4, up 12% year-over-year; full-year EPS of $5.28, an 11% increase.
• Free Cash Flow: Approximately $800 million in Q4, totaling $2.7 billion for the year, representing over 100% of net income.
• Shareholder Returns: $2 billion returned through dividends and share repurchases in 2025.

2. Strategic Updates and Business Highlights

• Growth Drivers: Strong performance in financial services, with 9% constant currency revenue growth in Q4 and 7% for the year, marking the highest annual level since 2016.
• Large Deals: Signed 12 large deals with total contract value (TCV) of $100 million or greater in Q4, including one deal over $1 billion.
• AI Engagements: Over 4,000 AI engagements, with 30% of software development efforts being AI-assisted.
• Acquisitions: Completed the acquisition of Three Cloud, adding 1,200 Azure specialists to enhance capabilities in AI and cloud services.
• Employee Development: Promoted over 35,000 associates and invested in AI training for 340,000 employees.

3. Forward Guidance and Outlook

• Q1 2026 Revenue Growth: Expected to be between 2.7% to 4.2% year-over-year in constant currency.
• Full-Year 2026 Revenue Growth: Projected to grow between 4% to 6.5% in constant currency, with an inorganic contribution of approximately 150 basis points.
• Adjusted Operating Margin Guidance: Expected to be between 15.9% to 16.1%.
• Adjusted Diluted EPS Guidance: Anticipated to be between $5.56 to $5.70, representing 5% to 8% year-over-year growth.

4. Bad News, Challenges, or Points of Concern

• Market Environment: The demand environment remains complex, with traditional discretionary spending cycles evolving, which could impact short-term bookings.
• Gross Margin Pressure: Higher variable compensation and the addition of Belcan, which has a lower gross margin profile, contributed to margin dilution.
• Regulatory Pressures: Ongoing regulatory changes in health sciences may pose challenges, although Cognizant sees opportunities for transformation in this sector.
• Pipeline Concerns: While large deal momentum is strong, there is some softness in smaller deal activity and annual contract value (ACV) growth.

5. Notable Q&A Insights

• AI Impact: Management emphasized that AI is a net positive for Cognizant, creating new opportunities rather than replacing existing revenue streams. They view AI as a catalyst for productivity and innovation.
• Fixed Price Contracts: Approximately 50% of contracts are now fixed price, which shifts more delivery risk to Cognizant. Management expressed confidence in their ability to manage these contracts effectively.
• Health Sciences Growth: Despite regulatory pressures, the health sciences segment is expected to grow due to the need for transformation and cost efficiencies.
• India Listing: Cognizant is evaluating a potential primary offering and secondary listing in India, with ongoing discussions with regulators but no definitive timeline provided.

Overall, Cognizant's Q4 2025 results reflect strong growth and strategic execution, particularly in AI and large deals, while also highlighting some challenges in the current market environment.